Danish CNS company Lundbeck announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness ...

Japanese drugmaker Kyowa Kirin late Friday announced the termination of the current rocatinlimab development and commercialization collaboration with US biotech major Amgen.

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

US biotech major Regeneron (Nasdaq: REGN) has presented its financial results for the fourth quarter and full year 2025.

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) has priced an $850 million offering of 5.5% senior unsecured notes due 2034 ...

UK pharma major AstraZeneca is strengthening its weight management portfolio through a new strategic collaboration agreement ...

Belgian biotech Agomab Therapeutics has set the terms for its planned US initial public offering, according to a filing with ...

Privately-held Swedish neuropathic pain specialist PharmNovo has announced changes to its board of directors, welcoming two ...

Germany-based Vetter Pharma has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.

The US Food and Drug Administration has accepted Summit Therapeutics’ (Nasdaq: SMMT) application for ivonescimab plus ...

South Korea’s Samsung Bioepis says it has signed a settlement and license agreement with Regeneron and Bayer concerning the commercialization of SB15, a biosimilar to Eylea 2mg (aflibercept 40mg/mL ...

US ophthalmology company SpyGlass Pharma has set out the terms of an initial public offering (IPO) in which the firms hopes ...